MRI with 75-cm core increases patient access and offers more services.
Global advanced imaging company United Imaging announced Tuesday it has received 510(k) clearance from the U.S. Food & Drug Administration for its uMR OMEGA MRI scanner.
With an ultra-wide 75-cm bore, the machine offers the widest bore on the market at any field strength, according to a company statement. The design is intended to accommodate a range of patients.
“The uMR OMEGA represents a critical advance for patients who will now have access to an enhanced patient experience and a more accommodating MRI scanning environment,” said Jeffrey Bundy, Ph.D. chief executive officer of UIH Solutions.
By offering a wider bore, he added, the uMR can better serve the 40 percent of Americans who are obese, as well as the 2.5 percent who have claustrophobia. Based on company details, the MRI scanner also includes a 680-lb table capacity, creating the first MRI imaging option for bariatric patients.
In addition, company officials said, the scanner provides new services, including acute imaging in the emergency room with a 5-minute stroke protocol and cardiac imaging with a single breath-hold that reduces the number of required scans. It is also a good solution for pediatric and geriatric patients who have difficulty remaining still for longer periods of time, they said.
“At United Imaging, we are all driven by patient experience: focusing on it, understanding it, improving it,” said Abram Voorhees, vice president of MR at UIH Solutions. “We intimately understand the anxiety that individuals can experience while undergoing an MRI, as well as the physical limitations of MRI machines today that can make a potentially life-saving study inaccessible. uMR OMEGA was created to remove the obstacles that often limit access for patients.”
The United States is the first company to receive the uMR with the first installation planned in United Imaging’s Houston showroom facility this summer.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).